.jpg)
13 hours ago
2
Article content
Strategic Partnership with Global Clinical Research Organization (CRO) Signifies Advancement in Clinical Development of Lucid-21-302 (Lucid-MS), a Novel First-in-Class Treatment Inhibiting Demyelination
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
TORONTO, March 30, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that it has entered into a binding Letter of Intent (LOI) with Allucent, a global contract research organization with extensive experience supporting central nervous system clinical trials, to support the planned Phase 2 clinical trial of Lucid-MS for the treatment of multiple sclerosis (MS).
Article content
Article content
Article content
This strategic partnership represents a significant milestone in Quantum BioPharma’s clinical development pipeline and underscores the Company’s commitment to advancing a potentially innovative solution for those MS patients suffering from debilitating mobility conditions unlike any solution in the market today.
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
The planned Phase 2 trial will evaluate the efficacy, safety and tolerability of Lucid-MS in people with MS. Quantum BioPharma expects to initiate the Phase 2 trial in the second quarter of 2026, subject to regulatory approvals and finalization of the clinical trial design and operational arrangements.
Article content
Under the terms of the LOI, Allucent will provide comprehensive clinical trial services designed to support efficient execution and data integrity throughout the study:
Article content
| Study Start-Up | Regulatory submissions, ethics approvals | Accelerated trial initiation |
| Site Selection & Management | Global site network coordination | Optimal patient access |
| Patient Recruitment | Enrollment strategy and execution | Efficient trial completion |
| Data Management | Collection, analysis, reporting | Rigorous clinical data integrity |
| Regulatory Support | Agency interactions, compliance | Streamlined development pathway |
Article content
Article content
The parties will finalize a more comprehensive and definitive services agreement in the coming weeks, solidifying this strategic partnership.
Article content
First-in-Class Potential Therapeutic Innovation for MS
Article content
Lucid-MS is designed to provide neuroprotection through the inhibition of demyelination—a key driver of disease progression in MS. This innovative mechanism represents a differentiated therapeutic approach in the global MS market, where many existing treatments primarily focus on modulating the immune system rather than addressing the underlying neurodegeneration.
Article content
“Lucid-MS is a First-in-Class, New Chemical Entity, Therapeutic Innovation designed to provide neuroprotection through the inhibition of demyelination, a key driver of disease progression in MS,” said Andrzej Chruscinski, Vice-President, Scientific and Clinical Affairs at Quantum BioPharma. “This innovative mechanism represents a differentiated therapeutic approach in the global MS market where an estimated 2.8 million people suffer and where many existing treatments primarily focus on modulating the immune system rather than addressing the underlying neurodegeneration. This Phase 2 trial will evaluate efficacy, safety and tolerability, while exploring the relationship between this mechanism and established clinical and radiographic markers of disease activity.”
English (US)